Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (773)	3/27/2007 12:46:31 PM
From: tuck	Read Replies (1) of 824

OT Re: BCRX Sounds to me like they'll drop that indication, possibly blow off development of the I.V. formulation altogether . . . >>Given the necessary delays associated with addressing the formulation issues now affecting the continued progress of the T-ALL trial, as well as the limited number of patients with T-ALL who are eligible to be treated under our protocol, BioCryst's strategy going forward will be to focus its resources on CTCL as the disease indication which the company believes could provide the fastest route to marketing approval of Fodosine(TM).<< They aren't having this issue with the CTCL trial because they are using an oral formulation in that one. The stumble slows burn down, but delays commercialization. Well, maybe not the latter given the apparently slow enrollment in the T-ALL trial, but that's how the Street is reading it, I think. So this might indeed be a good buy on this weakness. In any case, shall we move this over to the BCRX thread? Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next